Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical company advancing Haduvio™, an investigational oral therapy targeting chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), along with pruritic conditions like prurigo nodularis. This page provides comprehensive access to official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated updates on TRVI's research programs, regulatory milestones, and financial performance. Our news collection includes details on Haduvio's dual opioid receptor mechanism, trial design specifics, and collaborative initiatives – all essential for evaluating the company's scientific and commercial trajectory.
Key content categories include clinical trial results, FDA communications, intellectual property updates, executive leadership changes, and financial disclosures. Each update is presented with contextual clarity to serve both expert analysts and those new to biopharma investing.
Bookmark this page for streamlined access to TRVI's evolving story as it progresses through critical development phases. Check regularly for verified updates on therapeutic advancements directly from company filings and authorized communications.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, featuring a virtual fireside chat at 4:20 p.m. ET. The event will also include virtual investor meetings. Live webcasts can be accessed on the company's website, with a replay available for 30 days post-conference. Trevi is focused on the development of Haduvio (nalbuphine ER) for treating serious neurologically mediated conditions, including chronic cough and pruritus, currently conducting clinical trials for these indications.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announces the appointment of William Forbes as Chief Development Officer, effective immediately. Dr. Forbes, a seasoned professional with over 30 years in pharmaceutical product development, will oversee the clinical development of Haduvio™ (nalbuphine ER) for conditions like chronic pruritus and cough. Forbes previously held leadership roles at Vivelix Pharmaceuticals and Salix Pharmaceuticals, contributing to 12 FDA approvals. Trevi aims to fulfill unmet medical needs through Haduvio, currently in late-stage clinical trials.
Trevi Therapeutics (TRVI) reported updates on its clinical trials and financial results for Q3 2020. The PRISM trial for Haduvio, targeting severe pruritus, has surpassed halfway enrollment with approximately 190 subjects. The company aims to complete enrollment by Q3 2021 and report data by Q4 2021. In a phase 2 trial for chronic cough in IPF, new patient enrollment has resumed post COVID-19. As of September 30, 2020, Trevi's cash position was $53.3 million, expected to fund operations into H1 2022, with a Q3 net loss of $7.4 million.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 10:00 a.m. ET. The management will provide a company overview and conduct virtual investor meetings. Interested parties can access a live webcast of the presentation on Trevi's website, with an archived replay available for 30 days post-conference. Trevi Therapeutics focuses on developing Haduvio™, an investigational oral formulation of nalbuphine, aimed at treating serious neurologically mediated conditions like chronic pruritus.
Trevi Therapeutics (Nasdaq: TRVI) announces a conference call on November 11, 2020, at 4:30 p.m. ET to discuss Q3 2020 financial results and provide a corporate update. The call can be accessed by phone or via a live audio webcast on the company's website. Haduvio™ (nalbuphine ER), the company's lead drug, is being developed for serious neurologically mediated conditions, including chronic pruritus and levodopa-induced dyskinesia. Currently, Trevi is conducting a Phase 2b/3 trial, PRISM, for patients with severe pruritus.
Trevi Therapeutics, Inc. (TRVI) has resumed patient screening for its Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) after a pause due to COVID-19. The trial aims to enroll 60 subjects and investigate the efficacy of nalbuphine ER in reducing cough frequency. Additionally, the Phase 2b/3 PRISM trial for Haduvio in severe pruritus has reached 50% enrollment, with expectations to finish by Q3 2021 and report data by Q4 2021. The regulatory approval for protocol amendments enhances patient safety during the pandemic.
Trevi Therapeutics Updates Management Team
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced key appointments to enhance its clinical development and commercialization strategies for Haduvio™. Shashank Rohatagi, Ph.D. becomes Vice President of Pharmacology; Farrell Simon, Pharm.D. leads U.S. marketing; and Katherine S. Takaki, Ph.D. oversees global regulatory affairs. Dr. Rohatagi brings extensive regulatory experience, Dr. Simon has a strong commercial background from Pfizer, and Dr. Takaki has a proven record in regulatory strategy. Together, they aim to advance Haduvio’s development for serious conditions.
Trevi Therapeutics, a clinical-stage biopharmaceutical company focused on Haduvio (nalbuphine ER), announced its presentation at the 2020 H.C. Wainwright Global Investment Conference on September 16, 2020, at 3:00 p.m. ET. The presentation will outline the company’s development of Haduvio for conditions like chronic pruritus and chronic cough. A live webcast will be available on their website, with an archived version accessible for 30 days.
Trevi Therapeutics (Nasdaq: TRVI) announced a positive outcome in its PRISM trial following a sample size re-estimation, increasing target enrollment from 240 to 360 subjects. With COVID-19 restrictions lifted, patient enrollment has accelerated, and approximately 155 subjects have been recruited. The company secured a $14 million term loan to support operations into the first half of 2022. For Q2 2020, Trevi reported a net loss of $7.4 million, with cash and cash equivalents at $44.2 million, down from $57.3 million at year-end 2019.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will participate in the virtual 2020 BTIG Biotechnology Conference on August 10, 2020. Management will engage in a fireside chat at 11:00 a.m. ET, and virtual investor meetings will be hosted. Attendees can access a live webcast on the company’s website, with an archive available for 30 days post-conference. Trevi focuses on developing Haduvio™ (nalbuphine ER) for treating chronic pruritus, chronic cough in idiopathic pulmonary fibrosis patients, and levodopa-induced dyskinesia. Currently, it is in a Phase 2b/3 clinical trial for severe pruritus.
